A Leucine Aminopeptidase-Activated Theranostic Prodrug for Cancer Diagnosis and Chemotherapy

Feiyi Wang, Sisi Hu, Qi Sun, Qiang Fei, Chao Ma, Cuifen Lu, Junqi Nie, Zuxing Chen, Jun Ren, Guo Rong Chen, Guichun Yang, Xiao Peng He, Tony D. James

Research output: Contribution to journalArticle

Abstract

Currently, chemotherapy is a widely used and important treatment for cancer. However, almost all of the treatments have shortcomings associated with poor specificity and high toxicity, which results in severe side effects to normal cells and tissue. This is a very important problem, and yet, it currently remains unanswered. Therefore, the development of the method for the more effective delivery of anticancer drugs to their targets and real-time monitoring of the localization of the drugs are very important. Herein, we designed a theranostic prodrug: CPT-p-Leu, which was constructed using fluorescent camptothecin (CPT), a self-immolative linker and leucine (Leu) residue. Upon exposure to LAP (leucine aminopeptidase: LAP), the amide bond in CPT-p-Leu will be cleaved, followed by an intramolecular 1,6-elimination, which triggers the active anticancer drug (CPT) release and recovers the fluorescence of CPT. With our design, the anticancer drug, CPT, can be used as both a drug and a fluorescence reporter, making our system suitable to accurately and effectively track the released CPT distribution. Based on this strategy, CPT-p-Leu could achieve the chemoselective detection of LAP and monitoring of the anticancer drug release. Furthermore, it also provides a very convenient way to accurately determine the location of the released drug in living samples. In addition, CPT-p-Leu shows a good cell membrane permeability and enhanced cytotoxicity toward LAP overexpressing cancer cells. We anticipate that our research will facilitate the development of improved theranostic systems for cancer therapy.

Original languageEnglish
Pages (from-to)4904-4910
Number of pages7
JournalACS Applied Bio Materials
Volume2
Issue number11
Early online date11 Sep 2019
DOIs
Publication statusPublished - 18 Nov 2019

Keywords

  • bioimaging
  • chemotherapy
  • leucine aminopeptidase
  • sensor
  • theranostic prodrugs

ASJC Scopus subject areas

  • Biomaterials
  • Chemistry(all)
  • Biomedical Engineering
  • Biochemistry, medical

Cite this

A Leucine Aminopeptidase-Activated Theranostic Prodrug for Cancer Diagnosis and Chemotherapy. / Wang, Feiyi; Hu, Sisi; Sun, Qi; Fei, Qiang; Ma, Chao; Lu, Cuifen; Nie, Junqi; Chen, Zuxing; Ren, Jun; Chen, Guo Rong; Yang, Guichun; He, Xiao Peng; James, Tony D.

In: ACS Applied Bio Materials, Vol. 2, No. 11, 18.11.2019, p. 4904-4910.

Research output: Contribution to journalArticle

Wang, F, Hu, S, Sun, Q, Fei, Q, Ma, C, Lu, C, Nie, J, Chen, Z, Ren, J, Chen, GR, Yang, G, He, XP & James, TD 2019, 'A Leucine Aminopeptidase-Activated Theranostic Prodrug for Cancer Diagnosis and Chemotherapy', ACS Applied Bio Materials, vol. 2, no. 11, pp. 4904-4910. https://doi.org/10.1021/acsabm.9b00655
Wang, Feiyi ; Hu, Sisi ; Sun, Qi ; Fei, Qiang ; Ma, Chao ; Lu, Cuifen ; Nie, Junqi ; Chen, Zuxing ; Ren, Jun ; Chen, Guo Rong ; Yang, Guichun ; He, Xiao Peng ; James, Tony D. / A Leucine Aminopeptidase-Activated Theranostic Prodrug for Cancer Diagnosis and Chemotherapy. In: ACS Applied Bio Materials. 2019 ; Vol. 2, No. 11. pp. 4904-4910.
@article{adfda6ce1194489fb86355d8cdf6b6a2,
title = "A Leucine Aminopeptidase-Activated Theranostic Prodrug for Cancer Diagnosis and Chemotherapy",
abstract = "Currently, chemotherapy is a widely used and important treatment for cancer. However, almost all of the treatments have shortcomings associated with poor specificity and high toxicity, which results in severe side effects to normal cells and tissue. This is a very important problem, and yet, it currently remains unanswered. Therefore, the development of the method for the more effective delivery of anticancer drugs to their targets and real-time monitoring of the localization of the drugs are very important. Herein, we designed a theranostic prodrug: CPT-p-Leu, which was constructed using fluorescent camptothecin (CPT), a self-immolative linker and leucine (Leu) residue. Upon exposure to LAP (leucine aminopeptidase: LAP), the amide bond in CPT-p-Leu will be cleaved, followed by an intramolecular 1,6-elimination, which triggers the active anticancer drug (CPT) release and recovers the fluorescence of CPT. With our design, the anticancer drug, CPT, can be used as both a drug and a fluorescence reporter, making our system suitable to accurately and effectively track the released CPT distribution. Based on this strategy, CPT-p-Leu could achieve the chemoselective detection of LAP and monitoring of the anticancer drug release. Furthermore, it also provides a very convenient way to accurately determine the location of the released drug in living samples. In addition, CPT-p-Leu shows a good cell membrane permeability and enhanced cytotoxicity toward LAP overexpressing cancer cells. We anticipate that our research will facilitate the development of improved theranostic systems for cancer therapy.",
keywords = "bioimaging, chemotherapy, leucine aminopeptidase, sensor, theranostic prodrugs",
author = "Feiyi Wang and Sisi Hu and Qi Sun and Qiang Fei and Chao Ma and Cuifen Lu and Junqi Nie and Zuxing Chen and Jun Ren and Chen, {Guo Rong} and Guichun Yang and He, {Xiao Peng} and James, {Tony D.}",
year = "2019",
month = "11",
day = "18",
doi = "10.1021/acsabm.9b00655",
language = "English",
volume = "2",
pages = "4904--4910",
journal = "ACS Applied Biomaterials",
issn = "2576-6422",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - A Leucine Aminopeptidase-Activated Theranostic Prodrug for Cancer Diagnosis and Chemotherapy

AU - Wang, Feiyi

AU - Hu, Sisi

AU - Sun, Qi

AU - Fei, Qiang

AU - Ma, Chao

AU - Lu, Cuifen

AU - Nie, Junqi

AU - Chen, Zuxing

AU - Ren, Jun

AU - Chen, Guo Rong

AU - Yang, Guichun

AU - He, Xiao Peng

AU - James, Tony D.

PY - 2019/11/18

Y1 - 2019/11/18

N2 - Currently, chemotherapy is a widely used and important treatment for cancer. However, almost all of the treatments have shortcomings associated with poor specificity and high toxicity, which results in severe side effects to normal cells and tissue. This is a very important problem, and yet, it currently remains unanswered. Therefore, the development of the method for the more effective delivery of anticancer drugs to their targets and real-time monitoring of the localization of the drugs are very important. Herein, we designed a theranostic prodrug: CPT-p-Leu, which was constructed using fluorescent camptothecin (CPT), a self-immolative linker and leucine (Leu) residue. Upon exposure to LAP (leucine aminopeptidase: LAP), the amide bond in CPT-p-Leu will be cleaved, followed by an intramolecular 1,6-elimination, which triggers the active anticancer drug (CPT) release and recovers the fluorescence of CPT. With our design, the anticancer drug, CPT, can be used as both a drug and a fluorescence reporter, making our system suitable to accurately and effectively track the released CPT distribution. Based on this strategy, CPT-p-Leu could achieve the chemoselective detection of LAP and monitoring of the anticancer drug release. Furthermore, it also provides a very convenient way to accurately determine the location of the released drug in living samples. In addition, CPT-p-Leu shows a good cell membrane permeability and enhanced cytotoxicity toward LAP overexpressing cancer cells. We anticipate that our research will facilitate the development of improved theranostic systems for cancer therapy.

AB - Currently, chemotherapy is a widely used and important treatment for cancer. However, almost all of the treatments have shortcomings associated with poor specificity and high toxicity, which results in severe side effects to normal cells and tissue. This is a very important problem, and yet, it currently remains unanswered. Therefore, the development of the method for the more effective delivery of anticancer drugs to their targets and real-time monitoring of the localization of the drugs are very important. Herein, we designed a theranostic prodrug: CPT-p-Leu, which was constructed using fluorescent camptothecin (CPT), a self-immolative linker and leucine (Leu) residue. Upon exposure to LAP (leucine aminopeptidase: LAP), the amide bond in CPT-p-Leu will be cleaved, followed by an intramolecular 1,6-elimination, which triggers the active anticancer drug (CPT) release and recovers the fluorescence of CPT. With our design, the anticancer drug, CPT, can be used as both a drug and a fluorescence reporter, making our system suitable to accurately and effectively track the released CPT distribution. Based on this strategy, CPT-p-Leu could achieve the chemoselective detection of LAP and monitoring of the anticancer drug release. Furthermore, it also provides a very convenient way to accurately determine the location of the released drug in living samples. In addition, CPT-p-Leu shows a good cell membrane permeability and enhanced cytotoxicity toward LAP overexpressing cancer cells. We anticipate that our research will facilitate the development of improved theranostic systems for cancer therapy.

KW - bioimaging

KW - chemotherapy

KW - leucine aminopeptidase

KW - sensor

KW - theranostic prodrugs

UR - http://www.scopus.com/inward/record.url?scp=85074111686&partnerID=8YFLogxK

U2 - 10.1021/acsabm.9b00655

DO - 10.1021/acsabm.9b00655

M3 - Article

VL - 2

SP - 4904

EP - 4910

JO - ACS Applied Biomaterials

JF - ACS Applied Biomaterials

SN - 2576-6422

IS - 11

ER -